The estimated Net Worth of Shahzad Malik is at least $20.7 Million dollars as of 30 May 2018. Shahzad Malik owns over 236,984 units of Iterum Therapeutics Plc stock worth over $884,433 and over the last 17 years he sold ITRM stock worth over $19,807,954. In addition, he makes $0 as Independent Director at Iterum Therapeutics Plc.
Shahzad has made over 5 trades of the Iterum Therapeutics Plc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 236,984 units of ITRM stock worth $3,080,792 on 30 May 2018.
The largest trade he's ever made was selling 1,107,377 units of Iterum Therapeutics Plc stock on 8 May 2014 worth over $7,873,450. On average, Shahzad trades about 80,904 units every 65 days since 2007. As of 30 May 2018 he still owns at least 838,325 units of Iterum Therapeutics Plc stock.
You can see the complete history of Shahzad Malik stock trades at the bottom of the page.
Dr. Shahzad Malik, M.D., is Independent Director of the company. Since 1999, Dr. Malik has served as a general partner at Advent Life Sciences LLP, a venture capital firm. Prior to joining Advent, Dr. Malik spent six years practicing medicine before joining the London office of McKinsey & Company, a management consulting firm. Dr. Malik previously served on the boards of directors of Conatus Pharmaceuticals Inc., a pharmaceutical company, Agenus Inc., a biotechnology company, Aravive, Inc. (formerly Versartis, Inc.), a biopharmaceutical company, and Axonics Modulation Technologies, Inc., a medical technology company. Dr. Malik continues to serve on the boards of directors of a number of other private pharmaceutical and healthcare company boards. Dr. Malik holds an M.A. from Oxford University and an M.D. from Cambridge University. He subsequently specialized in interventional cardiology while also pursuing research interests in heart muscle disorders both in the clinic and basic science laboratory. Malik is qualified to serve on our board of directors due to his experience practicing medicine and his investment experience.
Shahzad Malik is 53, he's been the Independent Director of Iterum Therapeutics Plc since 2017. There are 7 older and 5 younger executives at Iterum Therapeutics Plc. The oldest executive at Iterum Therapeutics Plc is Dr. Michael W. Dunne M.D., 61, who is the Strategic Advisor & Director.
Shahzad's mailing address filed with the SEC is C/O ACUTUS MEDICAL, INC., 2210 FARADAY AVE., SUITE 100, CARLSBAD, CA, 92008.
Over the last 6 years, insiders at Iterum Therapeutics Plc have traded over $51,533,386 worth of Iterum Therapeutics Plc stock and bought 4,586,895 units worth $57,505,095 . The most active insiders traders include Capital Management, L.P.Ra ..., Alexander J Sarissa Capital..., and James Healy. On average, Iterum Therapeutics Plc executives and independent directors trade stock every 38 days with the average trade being worth of $474,585. The most recent stock trade was executed by Michael W. Dunne on 6 August 2024, trading 106,247 units of ITRM stock currently worth $112,091.
iterum therapeutics plc is an ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. these products are aimed at combatting the global crisis of multi-drug resistant (mdr) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. for more information on iterum therapeutics please visit www.iterumtx.com.
Iterum Therapeutics Plc executives and other stock owners filed with the SEC include: